Coherus Biosciences | CHRS - Current Assets

Stock Price
1.61
Daily Change
-0.40 -19.90%
Monthly
0.63%
Yearly
36.44%
Q1 Forecast
2.39

Coherus Biosciences reported $460.96M in Current Assets for its fiscal quarter ending in September of 2025.





Current Assets Change Date
AbbVie USD 28.54B 722M Sep/2025
Acadia Pharmaceuticals USD 1.08B 115.87M Sep/2025
Akebia Therapeutics USD 258.34M 23.68M Sep/2025
ALKERMES USD 1.74B 106.38M Sep/2025
Alnylam Pharmaceuticals USD 4.05B 97.85M Dec/2025
Amarin USD 628.33M 21.52M Sep/2025
Amgen USD 29.06B 1.17B Dec/2025
Baxter International USD 6.87B 61M Dec/2025
Biogen USD 8.97B 37.5M Dec/2025
BioMarin Pharmaceutical USD 3.85B 49.21M Sep/2025
Bristol-Myers Squibb USD 35.63B 2.41B Sep/2025
Coherus Biosciences USD 460.96M 80.75M Sep/2025
Eli Lilly USD 55.63B 6.44B Dec/2025
Fujifilm JPY 1.72T 120.76B Dec/2025
Gilead Sciences USD 19.89B 1.05B Dec/2025
Ironwood Pharmaceuticals USD 273.84M 82.09M Sep/2025
Merck USD 47.56B 10.49B Sep/2025
Myriad Genetics USD 344.8M 60.5M Sep/2025
Pacira USD 562.75M 182.86M Sep/2025
Perrigo USD 2.88B 264.2M Sep/2025
Pfizer USD 46.92B 3.22B Sep/2025
PTC Therapeutics USD 2.01B 265.07M Sep/2025
Regeneron Pharmaceuticals USD 18.02B 41.2M Dec/2025
Sarepta Therapeutics USD 2.72B 65.32M Sep/2025
Teva Pharmaceutical Industries USD 13.95B 1.21B Dec/2025
Vertex Pharmaceuticals USD 11.2B 631.4M Dec/2025
Xencor USD 518.44M 5.29M Sep/2025
Zoetis USD 6.77B 185M Dec/2025